



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid  
Drug Utilization Review (DUR) Board  
2pm  
Thursday, May 21, 2015  
DMAS Board Room 13<sup>th</sup> Floor

### Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair
2. Minutes
  - a. Approval of Minutes from November 20, 2014 meeting
3. New Drugs
  - a. Contrave<sup>®</sup> (naltrexone/bupropion)
  - b. Esbriet<sup>®</sup> (pirfenidone)
  - c. Ofev<sup>®</sup> (nintedanib)
  - d. Lynparza<sup>™</sup> (olaparib)
  - e. Soolantra<sup>®</sup> (ivermectin)
  - f. Tybost<sup>®</sup> (cobicistat)
  - g. Evotaz<sup>™</sup> (atazanavir sulfate/cobicistat)
  - h. PrezcoBix<sup>™</sup> (darunavir/cobicistat)
  - i. Vitekta<sup>®</sup> (elvitegravir)
  - j. Farydak<sup>®</sup> (panobinostat)
  - k. Ibrance<sup>®</sup> (palbociclib)
  - l. Lenvima<sup>™</sup> (lenvatinib)
  - m. New drugs: PDL-eligible; physician-administered injectables
4. Service Authorizations
  - a. Jakafi – new FDA approved indication for polycythemia vera
  - b. Kalydeco – now approved for patients age 2 years and older with specific gene mutations; new granule formulation
  - c. Imbruvica – now approved for Waldenström's macroglobulinemia
5. Reports
  - a. ProDUR
  - b. RetroDUR
  - c. Utilization Analysis
  - d. Top Diagnoses by Age
  - e. AAP Report



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

6. Topics for Discussion
  - a. Analysis of Compounded Medications – *follow up*
  - b. Morphine Equivalent Dosing for Narcotics
  - c. Synagis<sup>®</sup> utilization
7. First Data Bank's *Alert Space* Clinical Modules
8. Other Business
9. Adjournment